Tuberculin
As of the edition of 20 October 2026, Tuberculin is a drug: marketed, first approved in 1990 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Unknown
- Brand name
- Tuberculinum residuum (Tuberculinum residuum KOCH Nosode) C6
- First approved
- 1 June 1990 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Boiron; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Infections; Inherited and neonatal; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boiron | Applicant | 2013 to now |